Stand Up to Cancer Ovarian Cancer Dream Team Announced

April 21, 2015


Media Contact:

Kelly Voss, ED HERA Women’s Cancer Foundation


Stand Up to Cancer Ovarian Cancer Dream Team Announced

Denver, CO – April 21, 2014 – Local Denver nonprofit HERA Women’s Cancer Foundation is a contributing partner to the formation of a Dream Team devoted to ovarian cancer research that was announced yesterday by the American Association for Cancer Research (AACR).

Collaborating organizations, including HERA, will collectively devote $6 million over three years to a project entitled “DNA Repair Therapies for Ovarian Cancer.” The U.S. Food and Drug Administration (FDA) last year approved the drug olaparib to treat women with advanced ovarian cancer associated with defective BRCA genes, which are among a number of DNA repair genes identified as mutated in ovarian cancer. The existence of defects in DNA repair has emerged as a common weakness in ovarian cancer. By targeting DNA repair pathways, the Dream Team hopes to build and expand on the recent clinical advances seen with olaparib and other PARP inhibitors in current clinical trials. The team will also focus on prevention and early detection of ovarian cancer, which tends to be diagnosed at a late stage of the disease.

“Thanks to our supporters, this is an opportunity that will have great impact for the ovarian cancer community as a whole,” said Samantha Lockwood, HERA Board President. “As a ten year survivor of ovarian cancer and on behalf of the thousands of women and families affected by ovarian cancer who are looking to the world of science for answers, we are thrilled to be one of the organizations collaborating in this effort. Innovative research is the best hope we have for achieving better outcomes.”

The focus at HERA Women’s Cancer Foundation is eliminating ovarian cancer by funding scientific research grants. The Stand Up to Cancer Ovarian Cancer collaborative effort allows HERA to better leverage the $200,000 raised for this partnership.

Alan D’Andrea, MD, co-director of the Gene Therapy Center at Dana-Farber Cancer Institute in Boston, and the Fuller-American Cancer Society professor of medicine at Harvard Medical School, will lead the Dream Team. Elizabeth M. Swisher, MD, professor in the Department of Obstetrics and Gynecology at the University of Washington in Seattle, will be co-leader.

In addition to the team leaders, the project will involve researchers at Mayo Clinic in Rochester, Minnesota; University of Chicago; The University of Texas MD Anderson Cancer Center in Houston; and Memorial Sloan Kettering Cancer Center in New York. ###

news image strip